Loading
Cytokinetics Inc Stock: price and insider trades · United States
Cytokinetics Inc: what insiders have been doing
Cytokinetics Inc, founded in 1997, is a Healthcare & Pharma company based in South San Francisco, United States. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 20 insiders published 163 filings.
All open-market trades in the period are sales: 56 sales worth €21.9M, by 8 insiders, with no purchase on record. No amount is published for 6 filings, which the totals therefore leave out. One trade stands out by size: a sale of €5.9M from Blum Robert I, disclosed on 15 September 2026, or 0.074% of market capitalisation.
The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 163 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at no purchases and 147 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 88.0 m USD and net income at -785.0 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
631
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€44M
147 ops. · all time
Who traded when
BuySaleRobert I. Blum38 sales
Fady Ibraham Malik22 sales
Andrew Callos19 sales
Kaye Edward M. MD5 sales
B. Lynne Parshall4 sales
Harrington Robert Arthur4 sales
+3 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Cytokinetics Inc Strong Buy (bullish), based on 20 analysts. Average price target: US$109.90.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$66.16
Analyst consensus
20 analystsStrong buy
US$85.00Target US$109.90(+66%)US$146.00
Income statement
RevenueUS$88M
Gross profit-US$328M-373% margin
EBITDA-US$671M-762% margin
Net income-US$785M-891.6% margin
Valuation
PER (forward)-14.9x
Beta0.36
Balance sheet & cash
Market capUS$9.2B
Total debtUS$1.3B
Free Cash Flow-US$534.8M
Profitability & ownership
ROA-28.1%
% insiders0.6%
% institutions125.9%
Last declaration on 13 October 2026
Declarations631 total
22,500 shares@ US$62.910.015% mcap24.3% of flowCommonSEC144:0001950047-26-010157
7,500 shares@ US$10.600.0009% mcap0.3% of flowCommon StockSEC:0001061983-26-000099:0
7,500 shares@ US$62.880.0051% mcap1.5% of flowCommon StockSEC:0001061983-26-000099:1
3,500 shares@ US$7.800.0003% mcap0.2% of flowCommon StockSEC:0001061983-26-000098:0
3,500 shares@ US$61.380.0023% mcap1.6% of flowCommon StockSEC:0001061983-26-000098:1
7,500 shares@ US$10.600.0009% mcap0.3% of flowCommon StockSEC:0001061983-26-000097:0
7,500 shares@ US$65.460.0055% mcap1.6% of flowCommon StockSEC:0001061983-26-000097:1
3,500 shares@ US$7.800.0003% mcap0.2% of flowCommon StockSEC:0001061983-26-000096:0
3,500 shares@ US$68.290.0026% mcap1.7% of flowCommon StockSEC:0001061983-26-000096:1
97,926 shares@ US$72.45100.0% of flowCommon StockSEC144:0001968582-26-000978
97,926 shares0Common StockSEC:0001061983-26-000094:3
7,500 shares@ US$10.600.0009% mcap0.3% of flowCommon StockSEC:0001061983-26-000094:0
7,500 shares@ US$73.440.0060% mcap1.7% of flowCommon StockSEC:0001061983-26-000094:1
1,350 shares0Common StockSEC:0001061983-26-000094:2
97,926 shares0Common StockSEC:0001061983-26-000094:4
97,926 shares@ US$69.330.074% mcap21.6% of flowCommon StockSEC:0001061983-26-000094:5
1,000 shares@ US$72.130.0008% mcap49.3% of flowCommon StockSEC:0001061983-26-000095:0
2,000 shares@ US$73.620.0016% mcap100.0% of flowCommonSEC144:0001950047-26-009347
1,000 shares@ US$74.660.0008% mcap50.7% of flowCommon StockSEC:0001061983-26-000093:0
3,500 shares@ US$7.800.0003% mcap0.2% of flowCommon StockSEC:0001061983-26-000092:0
3,500 shares@ US$75.460.0029% mcap1.9% of flowCommon StockSEC:0001061983-26-000092:1
5,000 shares@ US$71.480.0039% mcap14.9% of flowCommon StockSEC:0001061983-26-000091:0
7,500 shares@ US$70.240.0058% mcap1.7% of flowCommon StockSEC:0001061983-26-000089:1
7,500 shares@ US$10.600.0009% mcap0.3% of flowCommon StockSEC:0001061983-26-000089:0
10,000 shares@ US$23.260.0025% mcap2.7% of flowCommon StockSEC:0001061983-26-000090:0
25 of 631 declarations
About Cytokinetics Inc
Cytokinetics, Incorporated (ticker: CYTK) is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States, with headquarters in South San Francisco, California. Founded in 1997 by pioneers in muscle biology, the company began operations in 1998 and later sharpened its focus on muscle dysfunction after discontinuing oncology research in 2008. That strategic pivot is important: Cytokinetics is not a broad, diversified pharma group, but a science-driven specialist built around the biology of muscle performance, especially in cardiac disease.
Cytokinetics’ core business is the discovery, development, and commercialization of medicines designed to alter muscle function. The company’s scientific platform centers on sarcomere biology and molecular motor proteins, and it has historically described its portfolio in terms of first-in-class muscle activators and next-in-class muscle inhibitors. Its lead commercial asset is MYQORZO® (aficamten), a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM). In 2025, aficamten achieved FDA approval in the U.S., and in 2026 the product also secured approvals in China and from the European Commission, marking a major transition from late-stage development to commercial execution.
Read moreShow less
From a market-positioning standpoint, Cytokinetics occupies a specialized, high-value niche in cardiovascular medicine. Its competitive edge comes from deep expertise in muscle biology, focused clinical development, and a differentiated mechanism of action rather than from scale. That focus can create meaningful barriers to entry and strong intellectual-property leverage, but it also concentrates risk around a relatively narrow therapeutic franchise. Recent clinical updates suggest the opportunity may extend beyond obstructive HCM: the company reported positive topline results in ACACIA-HCM, evaluating aficamten in non-obstructive hypertrophic cardiomyopathy, which could broaden the addressable market over time.
Geographically, Cytokinetics remains anchored in South San Francisco, United States, but its business is increasingly global as it advances regulatory and commercial milestones outside the U.S. Recent notable events include FDA approval of MYQORZO in 2025, regulatory approval in China in 2025, European Commission approval in 2026, and additional supportive data presented for aficamten at major medical congresses. For French-speaking investors, CYTK should be viewed as a specialized U.S. Nasdaq-listed cardiovascular biotech entering a new phase of commercialization, with its valuation and execution increasingly tied to the uptake of aficamten and the expansion of its cardiac pipeline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
